CompletedNot Applicable

Crohn's Disease - Inflammation and Microbial Proteolytic Activity

Canada30 participantsStarted 2019-12-01

Plain-language summary

This study postulates that altered microbiota associated with areas of mucosal inflammation in CD, can be characterized by an increased proteolytic profile. This is clinically important as it may be possible to modulate the proteolytic activity of the CD-associated bacteria by using other bacteria that produce protease inhibitors, such as serpins.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Be aged between 18 - 70 years old * Have a confirmed diagnosis of Crohn's disease * Have a clinical indication for standard, white light colonoscopy to assess disease activity and extent Exclusion Criteria: * Inability to provide written informed consent * Presence of serious life-threatening co-morbidities * Evidence of toxic megacolon, jaundice, cirrhosis, renal dysfunction, acute GI bleeding * History of difficult colonoscopy, strictures or extensive diverticulosis * Antibiotics in the last month * Probiotics in the last week

What they're measuring

Altered microbiota associated with areas of mucosal inflammation in CD, is characterized by an increased proteolytic profile

Timeframe: December 2019 - January 2025

Trial details

NCT IDNCT06503081

SponsorMcMaster University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-02-20

View on ClinicalTrials.gov More Crohn's Disease of Both Small and Large Intestine trials